Research description
My research interest mainly focuses on tumor immunology and immunotherapy. My research goal is to arm the rAAV vector with a necroptosis inducer, manipulate the tumor and its microenvironment to increase tumor immunogenicity and further understand the underlying mechanisms that the vaccination overcomes tumor induced immunosuppression. In addition, I also aim to explore new molecules in tumors that are critical to immunotherapy response.
FOCUS ON:
1) Developing oncolytic tumor vaccines for tumor immunotherapy
2) Exploring new molecules in tumors that are critical to immunotherapy response
3) Investigating the mechanisms underlying tumor vaccine immune responses and determinants of efficacy
Publications
(1) Wang W#, Lei Y#, Zhang G#, Li X, Yuan J, Li T, Zhong W, Zhang Y, Tan X, Song G. USP39 stabilizes β-catenin by deubiquitination and suppressing E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression. Cell Death Dis. 2023.
(2) Wang W#, Chong WP#, Li C#, Chen Z, Wu S, Zhou H, Wan Y, Chen W, Gery I, Liu Y, Caspi RR, Chen J. Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells. Cell report. 2019.
(3) Chong WP, Mattapallil MJ, Raychaudhuri K, Bing SJ, Wu S, Zhong Y, Wang W, Chen Z, Silver PB, Jittayasothorn Y, Chan CC, Chen J, Horai R, Caspi RR. The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24. Immunity. 2020.